Y. Teng, X. Xie, S. Walker, D. T. White, J. S. Mumm, and J. K. Cowell, “Evaluating human cancer cell metastasis in zebrafish,” BMC Cancer, vol. 13, no. 1, pp. 1–12, 2013.

R. L. Siegel, K. D. Miller, and A. Jemal, “Ca A Cancer Journal for Clinicians Cancer statistics,” Cancer statistics, vol. 56, no. 2, p. 106, 2015.

N. G. Zaorsky et al., “Causes of death among cancer patients,” Annals of oncology, vol. 28, no. 2, pp. 400–407, 2017.

S. A. Hafedh, N. H. Naser, and S. A. Hussein, “In silico study of novel naproxen derivatives bearing triazole moiety with promising anti-cancer activity,” vol. 140, no. 04, pp. 2535–2546, 2022.

T. N. Seyfried and L. C. Huysentruyt, “On the origin of cancer metastasis,” Crit Rev Oncog, vol. 18, no. 1–2, 2013.

M. T. P. Dukre, J. S. Shinde, and A. R. Bhavar, “A Review: Comprehensive Study on Anticancer Therapy,” 2021.

C. Shao et al., “Role of hypoxia-induced exosomes in tumor biology,” Mol Cancer, vol. 17, no. 1, pp. 1–8, 2018, doi: 10.1186/s12943-018-0869-y.

K. Wang, B. Yu, and J. L. Pathak, “An update in clinical utilization of photodynamic therapy for lung cancer,” J Cancer, vol. 12, no. 4, p. 1154, 2021.

L. Gatti and F. Zunino, “Overview of tumor cell chemoresistance mechanisms.,” Methods Mol Med, vol. 111, pp. 127–148, 2005, doi: 10.1385/1-59259-889-7:127.

S. Pastorekova, P. J. Ratcliffe, and J. Pastorek, “Molecular mechanisms of carbonic anhydrase IX‐mediated pH regulation under hypoxia,” BJU Int, vol. 101, pp. 8–15, 2008.

S. C. Frost, “Physiological functions of the alpha class of carbonic anhydrases,” Carbonic anhydrase: mechanism, regulation, links to disease, and industrial applications, pp. 9–30, 2014.

M.-C. Hsin, Y.-H. Hsieh, Y.-H. Hsiao, P.-N. Chen, P.-H. Wang, and S.-F. Yang, “Carbonic anhydrase IX promotes human cervical cancer cell motility by regulating PFKFB4 expression,” Cancers (Basel), vol. 13, no. 5, p. 1174, 2021.

S. Pastorekova, M. Zatovicova, and J. Pastorek, “Cancer-associated carbonic anhydrases and their inhibition,” Curr Pharm Des, vol. 14, no. 7, pp. 685–698, 2008.

D. C. Venugopal et al., “Integrated Proteomics Based on 2D Gel Electrophoresis and Mass Spectrometry with Validations: Identification of a Biomarker Compendium for Oral Submucous Fibrosis—An Indian Study,” J Pers Med, vol. 12, no. 2, p. 208, 2022.

Z. H. Chohan, A. U. Shaikh, A. Rauf, and C. T. Supuran, “Antibacterial, antifungal and cytotoxic properties of novel N-substituted sulfonamides from 4-hydroxycoumarin,” J Enzyme Inhib Med Chem, vol. 21, no. 6, pp. 741–748, 2006.

U. K. Mondal et al., “PEG linker length strongly affects tumor cell killing by PEGylated carbonic anhydrase inhibitors in hypoxic carcinomas expressing carbonic anhydrase IX,” Int J Mol Sci, vol. 22, no. 3, p. 1120, 2021.

A. Janoniene and V. Petrikaite, “In search of advanced tumor diagnostics and treatment: Achievements and perspectives of Carbonic Anhydrase IX targeted delivery,” Mol Pharm, vol. 17, no. 6, pp. 1800–1815, 2020.

C. T. Supuran, “Special Issue: Sulfonamides,” Molecules, vol. 22, no. 10, 2017, doi: 10.3390/molecules22101642.

O. M. Hendawy, “A comprehensive review of recent advances in the biological activities of 1, 2, 4‐oxadiazoles,” Arch Pharm (Weinheim), vol. 355, no. 7, p. 2200045, 2022.

R. M. M. El-Hazek, N. H. Zaher, H. E. S. Emam, M. G. El-Gazzar, and A. Khalil, “Pyrazole-sulfonamide scaffold featuring dual-tail strategy as apoptosis inducers in colon cancer,” Sci Rep, vol. 13, no. 1, p. 5782, 2023.

T. C. Denner, N. Heise, J. Zacharias, O. Kraft, S. Hoenke, and R. Csuk, “Small Structural Differences Govern the Carbonic Anhydrase II Inhibition Activity of Cytotoxic Triterpene Acetazolamide Conjugates,” Molecules, vol. 28, no. 3, p. 1009, 2023.

J.-J. Wang, W. Sun, W.-D. Jia, M. Bian, and L.-J. Yu, “Research progress on the synthesis and pharmacology of 1,3,4-oxadiazole and 1,2,4-oxadiazole derivatives: a mini review.,” J Enzyme Inhib Med Chem, vol. 37, no. 1, pp. 2304–2319, Dec. 2022, doi: 10.1080/14756366.2022.2115036.

M. J. Ahsan et al., “Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues,” Anticancer Agents Med Chem, vol. 18, no. 1, pp. 121–138, 2017, doi: 10.2174/1871520617666170419124702.

U. A. Atmaram and S. M. Roopan, “Biological activity of oxadiazole and thiadiazole derivatives.,” Appl Microbiol Biotechnol, vol. 106, no. 9–10, pp. 3489–3505, May 2022, doi: 10.1007/s00253-022-11969-0.

M. R. Sheehan, A. M. R. Raauf, and N. H. Naser, “In Silico Study and In Vitro Evaluation of Novel Synthesized Quinolone Derivatives Having Five-Membered Heterocyclic Moieties,” Egypt J Chem, vol. 65, no. 3, pp. 215–225, 2022, doi: 10.21608/ejchem.2021.92699.4390.

A. R. Saeed, N. H. Naser, and A. A. A. Alard, “Design, Synthesis and Pharmacological Evaluation of New Lomefloxacin Derivatives Having Oxadiazole Nucleus,” Journal of Pharmaceutical Sciences and Research, vol. 11, no. 4, pp. 1516–1526, 2019.

M. H. Mohammed, M. F. Mahdi, N. H. Naser, and S. M. Ali, “Design, synthesis and pharmacological evaluation of sulfanilamide-ciprofloxacin conjugates utilizing hybridization approach as new antibacterial agents,” J Nat Sci Res, vol. 15, no. 4, p. 106, 2015.

M. H. M. Noor Hatef Aldabagh, “Design, and synthesis of Novel Anti-tuberculosis Agents,” Scholar’s press, p. 69, 2017.

A. Tripathi and K. Misra, “Molecular docking: A structure-based drug designing approach,” JSM Chem, vol. 5, no. 2, pp. 1042–1047, 2017.